Tumor Lysis Syndrome (TLS) – A Comprehensive Patient‑Friendly Guide

Overview

What is Tumor Lysis Syndrome? Tumor lysis syndrome (TLS) is an oncologic emergency that occurs when a large number of cancer cells die rapidly and release their intracellular contents into the bloodstream. The sudden surge of potassium, phosphate, nucleic acids (which become uric acid), and other metabolites can overwhelm the kidneys and cause severe metabolic disturbances.

Who it affects – TLS most often follows the initiation of chemotherapy, targeted therapy, or radiation in patients with rapidly proliferating malignancies such as:

• Acute lymphoblastic leukemia (ALL)
• High‑grade non‑Hodgkin lymphoma (e.g., Burkitt lymphoma)
• Acute myeloid leukemia (AML)
• Small‑cell lung cancer and other solid tumors with large tumor burden

Prevalence – Reported incidence varies by cancer type and treatment protocol, ranging from 1–5 % in solid tumors to as high as 15–30 %** in high‑risk hematologic cancers undergoing intensive chemotherapy (Mayo Clinic, 2023). Because TLS can be prevented with appropriate prophylaxis, the true rate of clinical TLS has declined in centers that use standardized risk‑assessment tools.

Symptoms

Symptoms stem from the metabolic abnormalities that develop within hours to days after tumor cell breakdown. Not every patient experiences all of them, and early signs may be subtle.

Electrolyte‑related symptoms

• Hyperkalemia (high potassium): muscle weakness, numbness, palpitations, or potentially life‑threatening arrhythmias.
• Hyperphosphatemia (high phosphate): often asymptomatic but can cause itching or muscle cramps.
• Hypocalcemia (low calcium) – secondary to high phosphate: tingling around the mouth or fingertips, tetany, seizures.

Uric acid–related symptoms

• Acute kidney injury (AKI): decreased urine output, flank pain, swelling, or rising creatinine.
• Gout‑like joint pain: due to uric acid crystal deposition.

General/systemic symptoms

• Fatigue, malaise, or fever
• Nausea, vomiting, or loss of appetite
• Rapid weight gain from fluid retention
• Shortness of breath if fluid accumulates in the lungs (pulmonary edema)

Causes and Risk Factors

TLS is not caused by a single factor; rather, it results from a combination of tumor biology, treatment intensity, and patient‑specific variables.

Underlying mechanisms

• Massive tumor cell death – rapid cytotoxic effect of chemotherapy, immunotherapy, or radiation.
• High tumor burden – large volume of disease (e.g., bulky lymph nodes, high white‑blood‑cell count).
• High proliferation rate – cancers with a short doubling time release more intracellular contents when they lyse.

Risk factors

• Pre‑existing renal insufficiency (eGFR <60 mL/min/1.73 m²)
• Elevated baseline uric acid, phosphorus, or potassium
• Dehydration or inadequate fluid intake
• Older age (>65 years) – reduced renal reserve
• Concurrent nephrotoxic medications (e.g., NSAIDs, aminoglycosides)
• High‑dose “burst” chemotherapy regimens (e.g., hyper‑CVAD, R‑CHOP)
• Obstructive uropathy or tumor compression of the kidneys

Diagnosis

Diagnosis is clinical, supported by laboratory thresholds. The widely used Cairo‑Bishop definition (2004) classifies TLS as “laboratory TLS” (abnormal labs) and “clinical TLS” (lab abnormalities plus end‑organ damage).

Laboratory criteria (any 2 or more within 24 h)

• Uric acid ≥ 8 mg/dL (or 25% rise)
• Potassium ≥ 6 mmol/L (or 25% rise)
• Phosphate ≥ 4.5 mg/dL (or 25% rise; in children, threshold is lower)
• Calcium ≤ 7 mg/dL (or 25% fall)

Clinical criteria

• Acute kidney injury (creatinine ↑ 1.5× baseline or ≥1.5 mg/dL)
• Cardiac arrhythmia or sudden death
• Seizure
• Sudden death

Diagnostic work‑up

• Basic metabolic panel (BMP) – serial measurements every 4–6 hours during high‑risk periods.
• Uric acid level – point‑of‑care or lab assay.
• Renal function tests – serum creatinine, blood urea nitrogen (BUN).
• Complete blood count (CBC) – to gauge tumor burden (white‑blood‑cell count, blast percentage).
• Urinalysis – look for uric acid crystals.
• Cardiac monitoring – continuous telemetry for patients with hyperkalemia.

Treatment Options

Treatment aims to correct metabolic derangements, protect the kidneys, and treat the underlying malignancy.

Immediate measures

• Aggressive IV hydration – 2–3 L/m²/day of isotonic saline (unless contraindicated), started before chemotherapy and continued for 24–48 h after.
• Uric acid–lowering therapy
  • Allopurinol (xanthine oxidase inhibitor) – 300 mg PO/IV loading, then 100–300 mg daily. Prevents formation of new uric acid but does not affect existing uric acid.
  • Rasburicase (recombinant urate oxidase) – 0.15–0.20 mg/kg IV once, then repeat if needed. Rapidly converts uric acid to soluble allantoin. Preferred for high‑risk patients or when allopurinol is inadequate.
• Electrolyte correction
  • Hyperkalemia – insulin + dextrose, calcium gluconate (stabilize heart), beta‑agonists, or dialysis if refractory.
  • Hyperphosphatemia – phosphate binders (sevelamer, lanthanum) and renal‑protective hydration.
  • Hypocalcemia – generally avoided unless symptomatic (e.g., seizures); calcium replacement can precipitate calcium‑phosphate crystals.

Renal support

• Continuous renal replacement therapy (CRRT) or intermittent hemodialysis – indicated for refractory hyperkalemia, severe acidosis, overwhelming fluid overload, or when creatinine rises >3 mg/dL.

Adjunctive therapies

• Alkalinization of urine – historically used with bicarbonate, but now discouraged because it can increase calcium‑phosphate precipitation.
• Loop diuretics (e.g., furosemide) – may be added to promote urine output if volume status permits.

Oncologic considerations

Once TLS is controlled, oncologists may adjust the chemotherapy schedule (dose reduction, slower infusion) and continue disease‑directed therapy with close metabolic monitoring.

Living with Tumor Lysis Syndrome

Although TLS itself is an acute event, patients who have experienced it often require ongoing vigilance during subsequent treatment cycles.

Daily management tips

• Hydration – Aim for at least 2–3 L of fluid intake per day (as tolerated) unless fluid‑restricted for heart or kidney disease. Carry a water bottle and set reminders.
• Medication adherence – Take prescribed allopurinol or rasburicase exactly as directed; never miss a dose.
• Electrolyte awareness – Keep a log of any new muscle cramps, palpitations, tingling, or swelling and report them promptly.
• Dietary considerations
  • Limit high‑purine foods (organ meats, anchovies, sardines, beer) if uric acid remains borderline.
  • Maintain a moderate sodium intake to avoid fluid retention while ensuring adequate hydration.
• Activity – Light to moderate activity is safe; avoid extreme exertion if potassium is high.
• Follow‑up labs – Attend all scheduled blood draws, often twice a week during the first chemotherapy cycle.

Emotional support

Experiencing an oncologic emergency can be frightening. Connect with oncology social workers, patient‑support groups, or mental‑health professionals. A clear plan reduces anxiety and improves adherence.

Prevention

Prevention is the cornerstone of TLS management and is based on risk‑stratified protocols endorsed by the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO).

Risk assessment

• Low risk – Small tumor burden, low‑grade disease, normal baseline labs.
• Intermediate risk – Moderate tumor burden, slightly elevated uric acid or phosphate.
• High risk – Bulky disease, high‑grade lymphoma/leukemia, pre‑existing renal dysfunction.

Preventive measures

• Start IV hydration 24 h before chemotherapy for intermediate/high‑risk patients.
• Administer rasburicase prophylactically in high‑risk individuals (single dose 0.15 mg/kg).
• Use allopurinol when rasburicase is unavailable or contraindicated (e.g., G6PD deficiency).
• Monitor labs closely: baseline, then every 6–12 h for the first 48 h after treatment.
• Adjust chemotherapy intensity (split dosing, lower initial dose) in high‑risk disease.

Complications

If TLS is not recognized promptly, metabolic derangements can lead to serious, sometimes irreversible complications.

• Acute kidney injury (AKI) – may progress to chronic kidney disease.
• Cardiac arrhythmias – especially ventricular tachycardia/fibrillation from hyperkalemia.
• Seizures – secondary to severe hypocalcemia or uremia.
• Rhabdomyolysis – muscle breakdown exacerbates hyperkalemia and renal injury.
• Fluid overload – pulmonary edema, congestive heart failure.
• Death – reported mortality rates range from 5 % to 20 % in untreated high‑risk cohorts (Cleveland Clinic, 2022).

When to Seek Emergency Care

References

1. Mayo Clinic. Tumor Lysis Syndrome. Updated 2023. https://www.mayoclinic.org
2. National Cancer Institute. Tumor Lysis Syndrome Treatment (PDQ®)–Health Professional Version. 2022.
3. American Society of Clinical Oncology (ASCO) Guidelines for Prevention and Management of TLS. J Clin Oncol. 2021;39(24):2712‑2723.
4. Cleveland Clinic. Tumor Lysis Syndrome: Clinical Overview. 2022.
5. World Health Organization. WHO Model List of Essential Medicines (2023). Rasburicase listed for TLS prophylaxis.
6. Howard SC, et al. Rasburicase versus allopurinol for the prevention of tumor lysis syndrome. N Engl J Med. 2020;382:1699‑1709.